Exclusive special offer and discount title banner vector image

INDONESIA CANCER PAIN MANAGEMENT MARKET FORECAST 2024-2032

SCOPE OF THE REPORT

Indonesia  Cancer Pain Management Market by Drug Type (Opioids, Morphine, Non-opioids, Acetaminophen, Non-steroidal Anti-inflammatory Drugs, Nerve Blockers) Market by Disease Indication (Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Blood Cancer, Other Disease Indications)

REQUEST CUSTOMIZATION

MARKET OVERVIEW

The Indonesia cancer pain management market is expected to grow with a CAGR of 6.16% during the forecast period 2024-2032. Indonesia is experiencing a rise in cancer cases across its diverse population, with prevalent types including breast, cervical, lung, and colorectal cancers. This increase underscores a growing need for effective pain management solutions to enhance patient quality of life. According to the Global Cancer Observatory, Indonesia recorded 408,661 new cancer cases in 2022, highlighting the significant burden of the disease. As cancer rates continue to climb, there is an escalating demand for improved pain management strategies.

One contributing factor to this demand is Indonesia’s expanding elderly population, which numbered nearly 19 million in 2022. This demographic shift reflects broader trends in healthcare and increased life expectancy. Despite these advancements, access to advanced pain management treatments remains limited outside major cities, exacerbating disparities in healthcare resources across different regions of the country. The need for specialized pain management services, including palliative care, remains critical but often falls short in many areas.

Indonesia Cancer Pain Management Market

To Know More About This Report, Request a Free Sample Copy

The regulatory landscape and healthcare policies also play a crucial role in shaping the Indonesia cancer pain management market. Ongoing efforts to enhance healthcare services and access to cancer pain relief drugs are underway, yet there is a clear opportunity for further policy development and implementation. Government initiatives aimed at strengthening cancer care infrastructure, supporting healthcare providers, and promoting advancements in cancer treatment and pain management technologies are essential steps toward meeting these challenges comprehensively.

Need a custom report or have specific data requirements? Let us know!

The report on the Indonesia cancer pain management market includes the segmentation analysis based on drug type and disease indication.

Market by Drug Type:

  • Opioids
  • Morphine
    • Fentanyl
    • Other Morphines
  • Non-Opioids
  • Acetaminophen
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • Nerve Blockers

Market by Disease Indication:

  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Blood Cancer
  • Other Disease Indications

Inkwood Research’s report on the Indonesia cancer pain management market provides in-depth insights as well as the market’s segmentation analysis. The detailed evaluation of the market includes Competitive Landscape and Value Chain Analysis. 

Key players operating in the Indonesia cancer pain management market include Abbott, Hisamitsu Pharmaceutical Co Ltd, Pfizer, Teva Pharmaceutical Industries, PT Kalventis Sinergi Farma (Sanofi), etc.

Pfizer Inc is a biopharmaceutical firm that creates healthcare solutions ranging from preventing diseases to the treatment of chronic ailments and rare disorders. Pharmaceuticals, vaccines, and consumer healthcare are its three main business segments. Pfizer’s global activities include a substantial presence in North America, Europe, Asia, Latin America, and other locations. Its global headquarters are in New York City, the United States.

REPORT SYNOPSIS

REPORT SCOPEDETAILS
Market Forecast Years2024-2032
Base Year2023
Market Historical Years2018-2022
Forecast Units

Revenue ($ Million)

Segments Analyzed
Drug Type and Disease Indication
Countries AnalyzedIndonesia
Companies AnalyzedAbbott, Hisamitsu Pharmaceutical Co Ltd, Pfizer, Teva Pharmaceutical Industries, PT Kalventis Sinergi Farma (Sanofi)
TABLE OF CONTENTS
  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. METHODOLOGY
    3. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. COUNTRY SNAPSHOT — INDONESIA
    3. COUNTRY ANALYSIS — INDONESIA
    4. SCOPE OF STUDY
    5. CRISIS SCENARIO ANALYSIS
      1. IMPACT OF COVID-19 ON THE INDONESIA CANCER PAIN MANAGEMENT MARKET
    6. MAJOR MARKET FINDINGS
      1. INNOVATIONS IN PALLIATIVE CARE
      2. SURGE IN PERSONALIZED MEDICINE APPROACHES
      3. EXPANSION OF SPECIALIZED CANCER CARE FACILITIES
  3. MARKET DYNAMICS
    1. KEY DRIVERS
      1. RISING CANCER RATES IN INDONESIA
      2. GROWING ELDERLY POPULATION
      3. ENHANCED HEALTHCARE INFRASTRUCTURE
    2. KEY RESTRAINTS
      1. REGULATORY CHALLENGES AND APPROVAL DELAYS
      2. HIGH COST OF TREATMENT
      3. OPIOID SIDE EFFECTS AND ADDICTION CONCERNS
  4. KEY ANALYTICS
    1. KEY MARKET TRENDS
      1. ADVANCEMENTS IN MEDICAL TECHNOLOGY IN INDONESIA
      2. SUPPORTIVE GOVERNMENT POLICIES FOR CANCER PAIN MANAGEMENT
      3. ACTIVE R&D BY PHARMACEUTICAL COMPANIES 
    2. PESTLE ANALYSIS
      1. POLITICAL
      2. ECONOMICAL
      3. SOCIAL
      4. TECHNOLOGICAL
      5. LEGAL
      6. ENVIRONMENTAL
    3. PORTER’S FIVE FORCES ANALYSIS
      1. BUYERS POWER
      2. SUPPLIERS POWER
      3. SUBSTITUTIONS
      4. NEW ENTRANTS
      5. INDUSTRY RIVALRY
    4. GROWTH PROSPECT MAPPING — INDONESIA
    5. VALUE CHAIN ANALYSIS
      1. RESEARCH & DEVELOPMENT
      2. REGULATORY APPROVAL
      3. MANUFACTURING
      4. DISTRIBUTION
      5. END-USERS
  5. MARKET BY DRUG TYPE
    1. OPIOIDS
    2. MORPHINE
      1. FENTANYL
      2. OTHER MORPHINES
    3. NON-OPIOIDS
    4. ACETAMINOPHEN
    5. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
    6. NERVE BLOCKERS
  6. MARKET BY DISEASE INDICATION
    1. LUNG CANCER
    2. COLORECTAL CANCER
    3. BREAST CANCER
    4. PROSTATE CANCER
    5. BLOOD CANCER
    6. OTHER DISEASE INDICATIONS
  7. COMPETITIVE LANDSCAPE
    1. KEY STRATEGIC DEVELOPMENTS
      1. MERGERS & ACQUISITIONS
      2. PRODUCT LAUNCHES & DEVELOPMENTS
      3. PARTNERSHIPS & AGREEMENTS
      4. BUSINESS EXPANSIONS & DIVESTITURES 
    2. COMPANY PROFILES
      1. ABBOTT
        1. COMPANY OVERVIEW
        2. PRODUCTS
        3. STRENGTHS & CHALLENGES
      2. HISAMITSU PHARMACEUTICAL CO LTD
        1. COMPANY OVERVIEW
        2. PRODUCTS
        3. STRENGTHS & CHALLENGES
      3. PFIZER
        1. COMPANY OVERVIEW
        2. PRODUCTS
        3. STRENGTHS & CHALLENGES
      4. TEVA PHARMACEUTICAL INDUSTRIES
        1. COMPANY OVERVIEW
        2. PRODUCTS
        3. STRENGTHS & CHALLENGES
      5. PT KALVENTIS SINERGI FARMA (SANOFI)
        1. COMPANY OVERVIEW
        2. PRODUCTS
        3. STRENGTHS & CHALLENGES

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – CANCER PAIN MANAGEMENT

TABLE 2: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 3: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY DRUG TYPE, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 4: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY MORPHINE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 5: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY MORPHINE, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 6: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY DISEASE INDICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 7: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY DISEASE INDICATION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 8: LIST OF MERGERS & ACQUISITIONS

TABLE 9: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 10: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 11: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: GROWTH PROSPECT MAPPING – INDONESIA

FIGURE 4: VALUE CHAIN ANALYSIS

FIGURE 5: INDONESIA CANCER PAIN MANAGEMENT MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2023

FIGURE 6: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY OPIOIDS, 2024-2032 (IN $ MILLION)

FIGURE 7: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY MORPHINE, 2024-2032 (IN $ MILLION)

FIGURE 8: INDONESIA CANCER PAIN MANAGEMENT MARKET, GROWTH POTENTIAL, BY MORPHINE, IN 2023

FIGURE 9: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY FENTANYL, 2024-2032 (IN $ MILLION)

FIGURE 10: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY OTHER MORPHINES, 2024-2032 (IN $ MILLION)

FIGURE 11: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY NON-OPIOIDS, 2024-2032 (IN $ MILLION)

FIGURE 12: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY ACETAMINOPHEN, 2024-2032 (IN $ MILLION)

FIGURE 13: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2024-2032 (IN $ MILLION)

FIGURE 14: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY NERVE BLOCKERS, 2024-2032 (IN $ MILLION)

FIGURE 15: INDONESIA CANCER PAIN MANAGEMENT MARKET, GROWTH POTENTIAL, BY DISEASE INDICATION, IN 2023

FIGURE 16: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY LUNG CANCER, 2024-2032 (IN $ MILLION)

FIGURE 17: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY COLORECTAL CANCER, 2024-2032 (IN $ MILLION)

FIGURE 18: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY BREAST CANCER, 2024-2032 (IN $ MILLION)

FIGURE 19: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY PROSTATE CANCER, 2024-2032 (IN $ MILLION)

FIGURE 20: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY BLOOD CANCER, 2024-2032 (IN $ MILLION)

FIGURE 21: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY OTHER DISEASE INDICATIONS, 2024-2032 (IN $ MILLION)

FAQ’s

Request Customization
Request Customization
Request Free Sample